Agenus presents clinical data on botensilimab (next-gen CTLA-4)/balstilimab (PD-1) combination in heavily pretreated, treatment-resistant solid tumors
22% response rate and 73% disease control rate in MSS colorectal cancer
26% response rate and 63% disease control rate in recurrent platinum refractory/resistant ovarian cancer
42% response rate and 67% disease control rate in sarcomas
60% response rate and 80% disease control rate in PD-(L)1 relapsed/refractory NSCLC
AGEN1571 (anti-ILT2) enters clinical development
Preclinical data support best-in-class potential for Agenus' first wholly-owned clinical stage myeloid targeting agent
Agenus and BMS enter licensing agreement for AGEN1777 (TIGIT bispecific)
AGEN1777 enters clinical development
Agenus presents data on botensilimab (next-gen CTLA-4) in solid tumors
Botensilimab demonstrates clinical responses across nine cold and treatment-resistant cancer types
Agenus publishes data on balstilimab (PD-1)/zalifrelimab (CTLA-4) combination in 2L cervical cancer
Combination resulted in ~2x response rate (33%) vs. what has been reported for pembrolizumab in PD-L1+ patients
Agenus subsidiary MiNK Therapeutics announces IPO and becomes publicly traded on Nasdaq under the symbol INKT
MiNK is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases
Agenus subsidiary SaponiQx launches to drive innovation in adjuvant manufacturing, novel adjuvant discovery, and vaccine design
Agenus and Betta enter licensing agreement for balstilimab (PD-1) and zalifrelimab (CTLA-4) in greater China
Botensilimab (next-gen CTLA-4), AGEN2373 (CD137), and AGEN1423 (CD73-TGFβ) enter clinical development
Agenus and UroGen enter zalifrelimab collaboration for intravesical treatment of urinary tract cancers
MK-4830 (ILT4), INCAGN2385 (LAG-3) and INCAGN02390 (TIM-3) enter clinical development
Agenus and Gilead enter collaboration to develop next-generation immuno-oncology therapies
Balstilimab (PD-1) enters clinical development
FDA approves GSK’s Shingrix® containing QS-21 Stimulon™
Zalifrelimab (CTLA-4); INCAGN1949 (GITR) and INCAGN2385 (OX40) enter clinical development
Agenus and Incyte enter global I-O discovery alliance
Agenus acquires XOMA manufacturing plant and talent
Agenus acquires 4-AB with multiple checkpoint antibody programs
Agenus and Merck enter antibody discovery collaboration
Agenus completes IPO and becomes publicly traded on Nasdaq under the symbol AGEN
Agenus acquires Aquila Biopharmaceuticals and QS-21 Stimulon™
Potent immune adjuvant in GSK’s Shingrix® and Mosquirix™
Prophage reveals robust clinical responses in melanoma, renal cell carcinoma, colorectal cancer, and other indications
Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 781.674.4400 | F: +1 781.674.4200